Dou Yue, Zhu Mei, Dong Biao, Wang Ju-Xian, Zhang Guo-Ning, Zhang Fan, Wang Yu-Cheng
School of Pharmacy, Jinzhou Medical University, Jinzhou 121001, PR China.
Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, PR China.
Bioorg Med Chem Lett. 2020 Apr 1;30(7):127019. doi: 10.1016/j.bmcl.2020.127019. Epub 2020 Feb 5.
A series of novel HIV-1 protease inhibitors has been designed and synthesized, which contained morpholine derivatives as the P2 ligands and hydrophobic cyclopropyl as the P1' ligand at the meantime in this study, with the aim of improving the interactions between the active sites of HIV-1 protease and the inhibitors. Twenty-eight compounds were synthesized and assessed, among which inhibitors m18 and m1 exhibited excellent inhibitory effect on the activity of HIV-1 protease with IC value of 47 nM and 53 nM, respectively. The molecular modeling of m1 revealed possible hydrogen bondings or van der Waals between the inhibitor and the protease, worthy of in-depth study.
本研究设计并合成了一系列新型HIV-1蛋白酶抑制剂,其同时含有吗啉衍生物作为P2配体和疏水性环丙基作为P1'配体,目的是改善HIV-1蛋白酶活性位点与抑制剂之间的相互作用。合成并评估了28种化合物,其中抑制剂m18和m1对HIV-1蛋白酶活性表现出优异的抑制作用,IC值分别为47 nM和53 nM。m1的分子模拟显示抑制剂与蛋白酶之间可能存在氢键或范德华力,值得深入研究。